Liver International最新文献

{"title":"Plasma Ammonia Levels Over the Course of a Hospitalisation for Overt Hepatic Encephalopathy","authors":"Davide Erminelli,&nbsp;Chiara Mangini,&nbsp;Dario Gapeni,&nbsp;Lisa Zarantonello,&nbsp;Sara Montagnese","doi":"10.1111/liv.70365","DOIUrl":"https://doi.org/10.1111/liv.70365","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>The role of ammonia in the assessment of Overt Hepatic Encephalopathy (OHE) remains debated. The aim of the present study was to assess the time course of ammonia levels in relation to the severity and duration of an episode of OHE requiring hospitalisation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>104 patients discharged between January 2021 and July 2024 with a diagnosis of OHE were included [80 males, 72 ± 11 years]. Clinical and laboratory indices, including ammonia levels prior to/during/after the hospitalisation, were recorded, along with the duration of the hospitalisation, precipitants, ammonia-lowering and psychoactive treatment, where applicable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over the studied time frame, 58 (56%) patients had single OHE hospitalisations, while 20 (19%) had 2–7 OHE hospitalisations. Of the 104 hospitalisations, 30/63/7% were for OHE grades II/III/IV, respectively. Of the 58 single hospitalisations, 40/57/3% were for OHE grades II/III/IV, respectively. Ammonia levels increased significantly with increasing OHE grade; those prior to admission/after discharge were significantly lower than those on admission. Hospitalisations for grade IV OHE were longer. Ammonia levels on admission were lower in patients who were not fully recovered from OHE on discharge and those on chronic treatment with psychoactive drugs. All the above held true when analyses were restricted to the 58 single hospitalisations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ammonia levels correlated with OHE presence and severity, and with the duration of hospitalization. Incomplete recovery and chronic treatment with psychoactive drugs were associated with lower ammonia levels.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HBV Suppression by Nucleos(t)ide Analogues Reduces PD-1 Expression on Liver-Resident T Cells","authors":"Mireia García-López,&nbsp;Sabela Lens,&nbsp;Laura J. Pallett,&nbsp;Anna Pocurull,&nbsp;Thais Leonel,&nbsp;Ernest Belmonte,&nbsp;Ester García-Pras,&nbsp;Sergio Rodríguez-Tajes,&nbsp;Zoe Mariño,&nbsp;Maria Sàez-Palma,&nbsp;Concepción Bartres,&nbsp;Ariadna Rando-Segura,&nbsp;Francisco Rodríguez-Frías,&nbsp;Jonah Lin,&nbsp;Adam J. Gehring,&nbsp;Mala K. Maini,&nbsp;Xavier Forns,&nbsp;Sofía Pérez-del-Pulgar","doi":"10.1111/liv.70338","DOIUrl":"https://doi.org/10.1111/liv.70338","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>PD-1-expressing T cells within the HBV-infected liver constitute a target of novel immunotherapeutics. Our aim was to investigate the impact of viral suppression on PD-1 expression on intrahepatic versus circulating lymphocyte populations from chronic hepatitis B (CHB) patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Twenty-two CHB patients, nine of them on nucleos(t)ide analogues (NUCs), had paired blood, liver fine needle aspirations (FNAs) and biopsies. A subset had a follow-up FNA after treatment initiation (<i>n</i> = 4) or discontinuation (<i>n</i> = 4). Intrahepatic (iHBV-DNA and cccDNA) and serum (HBV-DNA, HBsAg, HBcrAg and cirB-RNA) viral markers were quantified. Flow cytometry was used for immunophenotyping PBMCs and intrahepatic lymphocytes. An independent liver FNA scRNAseq dataset was used to consolidate our results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PD-1 expression on tissue-resident memory CD8 T cells (T_RM) correlated with both iHBV-DNA and cccDNA, as well as surrogate markers of cccDNA transcriptional activity (cirB-RNA and HBcrAg) in CHB patients with mild hepatitis. These associations were not reflected in circulating T cells. PD-1 expression intensity on CD8 T_RM was lower in NUC-treated than in naive patients, changes that were again not detectable in the circulation. Longitudinal analysis showed that viral load rebound induced by NUC discontinuation had the potential to drive re-expression of high levels of PD-1 on CD8 T_RM. Conversely, therapy initiation and subsequent viral suppression reversed these changes. scRNAseq results further extended the profiling of these PD-1 + CD8 T_RM, showing a phenotype consistent with bystander activation in response to subclinical liver damage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Intrahepatic viral markers correlate with PD-1 expression on global liver-resident T cells of CHB patients with mild hepatitis, with a reduction after prolonged NUC therapy and re-expression following treatment withdrawal.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI Based on LI-RADS Version 2018 and LI-RADS Modifications","authors":"Yanjin Qin,&nbsp;Jing Zhang,&nbsp;Danyang Xu,&nbsp;Xiaoqi Zhou,&nbsp;Zhoukun Ling,&nbsp;Lujie Li,&nbsp;Qiaochu Zhao,&nbsp;Zhi Dong,&nbsp;Jifei Wang,&nbsp;Hua-Song Cai,&nbsp;Hongxiang Li,&nbsp;Lie-Guang Zhang,&nbsp;Shi-Ting Feng","doi":"10.1111/liv.70366","DOIUrl":"https://doi.org/10.1111/liv.70366","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 (v2018), its modifications modified LI-RADS (mLI-RADS) and revised LI-RADS (rLI-RADS), for diagnosing hepatocellular carcinoma (HCC) remains poorly understood and requires further validation. This multicentre study aimed to evaluate the diagnostic performance of three algorithms in diagnosing HCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included 1092 untreated patients at risk for developing HCC who underwent gadoxetic acid–enhanced MRI across three independent cohorts from January 2020 to December 2022. Two readers independently interpreted each hepatic lesion and recorded their imaging features. The readers' judgements regarding whether the lesion was HCC or not were also noted. Non-HCC cases were confirmed based on histologic and clinical follow-up data, while HCC cases were pathologically confirmed. Diagnostic performance metrics were compared using bootstrap resampling and generalised estimating equations. Additionally, the diagnostic odds ratio (DOR) was evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 1313 lesions, 52.3% (687/1313) were diagnosed as HCC. For all hepatic lesions, mLI-RADS achieved higher sensitivity (82.9%) and accuracy (84.1%) than LI-RADS v2018 (sensitivity, 79.9%, <i>p</i> = 0.024; accuracy, 83.2%) and rLI-RADS (sensitivity, 81.3%; accuracy, 83.8%), while maintaining a similar positive predictive value (mLI-RADS, 86.2%; LI-RADS v2018, 86.9%; rLI-RADS, 86.9%). The DORs were 28.3 (95% CI: 21.1–38.0) for mLI-RADS, 27.8 (95% CI: 20.6–37.7) for LI-RADS v2018 and 26.0 (95% CI: 19.3–35.0) for rLI-RADS. The readers' judgement exhibited higher accuracy than that of three algorithms (87.7%: 83.2%–84.1%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>For the diagnosis of HCC in an HBV-predominant cohort, mLI-RADS showed higher performance compared with LI-RADS v2018 and rLI-RADS. Reader judgement achieved higher accuracy than all algorithms, highlighting the role of clinical expertise.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>NCT06663904</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-25 Improves MAFLD by Suppressing the Notch Signalling in Hepatic Macrophages","authors":"Xuelian Zheng,&nbsp;Dandan Hu,&nbsp;Dongjing Zhang,&nbsp;Ye Chen,&nbsp;Jianrui Wei,&nbsp;Bo Xie,&nbsp;Anjiang Wang","doi":"10.1111/liv.70370","DOIUrl":"https://doi.org/10.1111/liv.70370","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Hepatic steatosis is characterised by hepatic lipid accumulation, inflammation and fibrosis, with macrophage polarisation playing a central role in disease progression. This study investigates the role of interleukin-25 (IL-25) in modulating macrophage polarisation and Notch signalling in a methionine-choline-deficient (MCD) diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>C57BL/6 mice were fed a MCD diet to induce MAFLD. Human hepatocytes and primary hepatic macrophages were treated with palmitic acid and/or IL-25. Methods included RT-qPCR, ELISA, Western blot and immunofluorescence for gene/protein expression. ChIP and luciferase assays were used to analyse STAT3/Notch-1 signalling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that IL-25 expression was significantly downregulated in the livers of MCD-fed mice and in palmitic acid-treated hepatocytes. IL-25 treatment promoted M2 macrophage polarisation, evidenced by increased expression of Arg1, Chi3l3 and anti-inflammatory cytokines (IL-10, TGF-β), while suppressing pro-inflammatory cytokines (TNF-α, IL-6). Mechanistically, IL-25 inhibited the STAT3/Notch-1 pathway and induced IL-33, which negatively regulated the NF-κB/Jagged-1 axis, preventing M1 macrophage polarisation. Adoptive transfer of IL-25-induced M2a macrophages ameliorated hepatic steatosis and reduced ductular reaction in MCD-fed mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest a role for IL-25 in modulating macrophage polarisation and inflammation in metabolic dysfunction-associated fatty liver disease, supporting its further exploration as a potential therapeutic strategy for inflammatory liver diseases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Depletion of Plasma Cells but Not CD20+B Cells Alleviates Primary Biliary Cholangitis","authors":"Xue Zhang,&nbsp;Hao Jia,&nbsp;Ying Ran,&nbsp;Hongyu Chu,&nbsp;Meng Shen,&nbsp;Hui Yang,&nbsp;Zongze Han,&nbsp;Xiaoyi Wang,&nbsp;Jiwen Li,&nbsp;Yanni Li,&nbsp;Man Liu,&nbsp;Shijing Dong,&nbsp;Zhen Yang,&nbsp;Simin Zhou,&nbsp;Liping Guo,&nbsp;Yujie Zhang,&nbsp;Bangmao Wang,&nbsp;Jihua Shi,&nbsp;Long Li,&nbsp;Lu Zhou","doi":"10.1111/liv.70373","DOIUrl":"10.1111/liv.70373","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>The hepatic inflammatory infiltrates in patients with primary biliary cholangitis (PBC) contain variable numbers of B cells and plasma cells; however, their potential as therapeutic targets remains uncertain. This study aims to investigate the pathological characteristics and therapeutic implications of plasma cells and B cells in PBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected liver tissue from 55 PBC patients, alongside serological data from the time of sampling and 1 year following ursodeoxycholic acid (UDCA) treatment. To evaluate the effects of plasma cell and B cell depletion, we utilised dnTGF-βRII mice treated with bortezomib and anti-CD20 monoclonal antibody, respectively. Additionally, we performed an adoptive transfer of plasma cells from dnTGF-βRII mice into C57BL/6J mice to investigate their pathogenicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In PBC patients, hepatic infiltration of plasma cells and B cells was correlated strongly with liver inflammation and fibrosis, disease staging, and titers of PBC-related autoantibodies. The number of plasma cells (but not B cells) was also higher in UDCA non-responders than in responders. Notably, plasma cells depletion in dnTGF-βRII mice alleviated portal inflammation and reduced levels of AMA, IgM and IgG. Furthermore, the adoptive transfer of plasma cells from dnTGF-βRII mice into DDC-fed C57BL/6J mice resulted in AMA production, exacerbated cholestasis, and worsened fibrosis. In contrast, B cell depletion did not alleviate portal inflammation or fibrosis in dnTGF-βRII mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The data indicate a pathogenic role for plasma cells in PBC. The depletion of plasma cells alleviated cholangitis in PBC mice, indicating a promising new therapeutic strategy for PBC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Determinants in Patients With Cirrhosis and Septic Shock: Beyond Relative Adrenal Insufficiency","authors":"Philippe Meersseman,&nbsp;Alexander Wilmer,&nbsp;Javier Fernandez","doi":"10.1111/liv.70382","DOIUrl":"10.1111/liv.70382","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation","authors":"Efe Ozkaya,&nbsp;Octavia Bane,&nbsp;Enamul Bhuiyan,&nbsp;Amine Geahchan,&nbsp;Emre Altinmakas,&nbsp;Stefanie J. Hectors,&nbsp;Paul Kennedy,&nbsp;Ghadi Abboud,&nbsp;Swathi Pavuluri,&nbsp;Richard L. Ehman,&nbsp;Meng Yin,&nbsp;Sara Lewis,&nbsp;Meena B. Bansal,&nbsp;Aaron Fischman,&nbsp;Swan Thung,&nbsp;Thomas D. Schiano,&nbsp;Bachir Taouli","doi":"10.1111/liv.70368","DOIUrl":"https://doi.org/10.1111/liv.70368","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Clinically significant portal hypertension (CSPH; hepatic venous pressure gradient (HVPG) ≥ 10 mmHg) is a severe complication of chronic liver disease, with increased risk of variceal bleeding and liver decompensation (at HVPG ≥ 12 mmHg). This study evaluated the performance of multiparametric (mp)MRI for diagnosing CSPH and predicting liver decompensation, compared to ultrasound-based shear wave elastography (SWE) and blood tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective single-centre study (2018–2022), 59 patients (M 30, mean age 52.7 years) underwent mpMRI and HVPG measurement, with an average interval of 32 ± 31 days. The mpMRI protocol included 2D/3D MR elastography (MRE), T₁/proprietary iron-compensated T₁ (cT₁)/T_1ρ mapping, gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) of the liver and spleen, SWE and blood tests. Statistical analyses included Mann–Whitney U tests, ROC analysis, logistic regression and Cox proportional hazards models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CSPH was present in 13 patients (22%). Several MRI parameters showed high diagnostic performance for CSPH (AUC ≥ 0.8), with spleen stiffness-2D MRE (AUC 0.88, 95% confidence interval (CI) 0.78–0.98) and liver uptake on DCE-MRI (AUC 0.83, 95% CI 0.70–0.96) performing best, while SWE had AUCs of 0.63 (95% CI 0.45–0.81) for liver and 0.67 (95% CI 0.44–0.89) for spleen. Combining spleen stiffness-2D MRE and liver uptake achieved an AUC of 0.93 (95% CI 0.86–1.00) for diagnosing CSPH. For predicting decompensation, spleen stiffness-3D MRE and liver uptake rate had AUCs of 0.83 (95% CI 0.68–0.99) and 0.83 (95% CI 0.70–0.95), respectively, outperforming SWE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Spleen stiffness measured with MRE combined with gadoxetate liver uptake (measured with DCE-MRI) can diagnose CSPH and predict liver decompensation, with superior performance compared to SWE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT03436550</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing Key Modelling Assumptions in the Cost-Effectiveness of Treating High Viremic Indeterminate-Phase Chronic Hepatitis B","authors":"Xin Xu","doi":"10.1111/liv.70294","DOIUrl":"https://doi.org/10.1111/liv.70294","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics-Based Prognostication in Primary Sclerosing Cholangitis: A Proof-of-Concept Study","authors":"Laura Cristoferi,&nbsp;Cesare Maino,&nbsp;Davide Paolo Bernasconi,&nbsp;Ilaria Ripamonti,&nbsp;Miki Scaravaglio,&nbsp;Alberto Savino,&nbsp;Eugenia Pesatori,&nbsp;Alessio Gerussi,&nbsp;Eugenia Nofit,&nbsp;Olga Falco,&nbsp;Daphne D'Amato,&nbsp;Francesca Gallivanone,&nbsp;Chiara Alberzoni,&nbsp;Raffaella Viganò,&nbsp;Chiara Mazzarelli,&nbsp;Luca Saverio Belli,&nbsp;Marco Emilio Dinelli,&nbsp;Massimiliano Mutignani,&nbsp;Maria Grazia Valsecchi,&nbsp;Rocco Corso,&nbsp;Pietro Invernizzi,&nbsp;Marco Carbone,&nbsp;Davide Ippolito,&nbsp;Elisabetta De Bernardi","doi":"10.1111/liv.70348","DOIUrl":"https://doi.org/10.1111/liv.70348","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Risk assessment in primary sclerosing cholangitis (PSC) by magnetic resonance imaging (MRI) relies on semi-quantitative analysis, which can result in interpretation variability. Radiomics may offer a quantitative approach for risk stratification. This study aims to explore and validate MRI-derived radiomic features to identify high-risk PSC patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective study (January 2019–December 2022), consecutive PSC patients undergoing routine gadoxetate disodium-enhanced MRI were recruited. Using PyRadiomics, whole liver parenchyma features were extracted from five MRI sequences according to the Image Biomarker Standardisation Initiative (IBSI). Patients were categorised into risk groups based on the Mayo risk score (MRS) and liver stiffness measurement (LSM). Features associated with high-risk patients were selected and validated in an independent cohort. A survival analysis was conducted in the combined cohort to assess the prognostic value of the radiomic features for clinical events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and two PSC patients were enrolled in this study. Five radiomics features were associated with high risk in the training cohort. In the validation setting, <i>GLRLM-Run Entropy</i> in the fat-saturation T2 weighted imaging (FS-T2W) sequence was the only significant feature, with an odds ratio of 3.90 (CI 1.46–10.42, <i>p</i> = 0.007) for MRS and 2.97 (CI 1.33–6.66, <i>p</i> = 0.008) for LSM. Its prognostic potential on clinical outcome was confirmed by Cox regression analysis in the combined cohort (hazard ratio per 0.1 increase = 1.480, CI 1.226–1.786), showing excellent predictive performance (C-index = 0.857).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>GLRLM-Run Entropy</i> in FS-T2W is a novel radiomics-based biomarker for risk stratification in PSC patients. It is quantitative, standardised, easy to compute and cost-free, positioning it as a potential key innovation in PSC radiology-based biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Clinicaltrial.gov ID: NC705618145</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yes-Associated Protein in Hepatocytes Protects Against Early Alcohol-Associated Liver Disease","authors":"Xin Zhang,&nbsp;Xinpu Yang,&nbsp;Xia Sun,&nbsp;Qiaohong Qin,&nbsp;Ying Hou,&nbsp;Min Jia,&nbsp;Xingli Su,&nbsp;Yulong Chen","doi":"10.1111/liv.70372","DOIUrl":"https://doi.org/10.1111/liv.70372","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Alcohol-associated liver disease (ALD) is a current unmet clinical challenge attributed to a lack of effective pharmacological therapy. Yes-associated protein (YAP) is a transcriptional co-activator and has been extensively investigated in liver diseases. However, the role of YAP in ALD is still unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The early ALD mouse model was induced using a Gao-binge diet. Furthermore, the function of hepatic YAP in ALD was investigated using YAP^−/− mice, mice injected with an adeno-associated virus (AAV) 9-delivered saCas9/sgYAP system (AAV9-saCas9/sgYAP), or YAP^ΔHep mice fed the Gao-binge diet. The mechanisms underlying hepatocellular YAP-regulated ALD were further studied in the YAP^ΔHep mice. The therapeutic efficacy of hepatocellular YAP expression was tested using AAV8-delivered YAP overexpression in mice fed the Gao-binge diet.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In response to the Gao-binge diet, whole-body YAP deficiency exacerbated early ALD-related phenotypes in mice, including hepatic steatosis and inflammatory response. Furthermore, the YAP^ΔHep mice also exhibited aggravated ALD-related phenotypes. However, hepatocyte-specific YAP or YAP (5S) overexpression substantially reversed the disease progression in the YAP^ΔHep mice. Mechanistically, hepatocellular YAP inhibited hepatic steatosis, inflammatory response and fibrosis through down-regulating CD36. Furthermore, the oncostatin (OSM)–STAT3 axis was involved in YAP-mediated regulation of CD36. Notably, we also found that AAV8-Alb-YAP effectively ameliorated the progression of early ALD in mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Hepatocellular YAP functions as a negative regulator of pathological changes by inhibiting the OSM-STAT3-CD36 pathway during early ALD, representing a potential therapeutic target for early ALD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 11","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}